文献速递冠心病

经皮冠状动脉介入治疗基线血小板计数的剂量反应Meta分析

Baseline platelet count in percutaneous coronary intervention: a dose-response meta-analysis.
PubMed 文献 · Heart · 2022-05-25

结果显示基线血小板计数与全因死亡、MACE及大出血呈J型关系:低血小板计数(<175×10^9/L)时出血风险超过血栓风险,高血小板计数(>250×10^9/L)时以缺血风险为主。

要点

  • 基线血小板计数与PCI后全因死亡、MACE及大出血呈J型关系。
  • 血小板计数<175×10^9/L时出血风险超过血栓风险。
  • 血小板计数>250×10^9/L时以缺血风险为主。

核心结论

  • 低血小板计数与以出血风险为主相关,高血小板计数仅与缺血事件相关。

研究设计与样本

  • 检索PubMed、Scopus和Web of Science截至2021年10月9日。
  • 采用随机效应配对及一阶段剂量反应Meta分析,计算HR和95%CI。

主要发现

  • 基线血小板计数与全因死亡、MACE及大出血在随访期间呈J型关系。
  • 低血小板计数(<175×10^9/L)时出血事件风险超过血栓事件风险。
  • 高血小板计数(>250×10^9/L)时以缺血风险为主。
  • 血小板减少症与出院后全因死亡(HR 1.39,95%CI 1.30-1.49)及大出血(HR 1.51,95%CI 1.15-2.00)相关。
  • 血小板增多症与全因死亡(HR 1.60,95%CI 1.29-1.98)及MACE(HR 1.47,95%CI 1.22-1.78)相关。

临床怎么用

  • PCI患者基线血小板计数可用于风险分层,低值关注出血、高值关注缺血事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The nature of the relationship between baseline platelet count and clinical outcomes following percutaneous coronary intervention (PCI) is unclear. We undertook dose-response and pairwise meta-analyses to better describe the prognostic value of the initial platelet count and clinical endpoints in patients after PCI. METHODS: A search of PubMed, Scopus and Web of Science (up to 9 October 2021) was performed to identify studies that evaluated the association between platelet count and clinical outcomes following PCI. The primary outcomes of interest were all-cause mortality, major adverse cardiovascular events (MACE) and major bleeding. We performed random-effects pairwise and one-stage dose-response meta-analyses by calculating HRs and 95% CIs. RESULTS: The meta-analysis included 19 studies with 217 459 patients. We report a J-shaped relationship between baseline thrombocyte counts and all-cause death, MACE and major bleeding at follow-up. The risk of haemorrhagic events exceeded the risk of thrombotic events at low platelet counts (<175×109/L), while a predominant ischaemic risk was observed at high platelet counts (>250×109/L). Pairwise meta-analyses revealed a robust link between initial platelet counts and the risk of postdischarge all-cause mortality, major bleeding (for thrombocytopenia: HR 1.39, 95% CI 1.30 to 1.49; HR 1.51, 95% CI 1.15 to 2.00, respectively) and future death from any cause and MACE (thrombocytosis: HR 1.60, 95% CI 1.29 to 1.98; HR 1.47, 95% CI 1.22 to 1.78, respectively). CONCLUSION: Low platelet counts were associated with the predominant bleeding risk, while high platelet counts were only associated with the ischaemic events. PROSPERO REGISTRATION NUMBER: CRD42021283270.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Galimzhanov, Sabitov, Tenekecioglu, et al. Baseline platelet count in percutaneous coronary intervention: a dose-response meta-analysis. Heart. 2022. PMID: 35613715. doi:10.1136/heartjnl-2022-320910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。